📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-28 17:15
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
17 announcements match the current filters (relevance ≥ 5).
Fischer Medical Ventures Launches CLARION 64/128-Slice AI-Driven CT Scanner System
Fischer Medical Ventures Limited's wholly owned subsidiary, Time Medical International Ventures (TMIV Imaging), has launched its next-generation CLARION 64/128-Slice AI-driven CT system at the India Health Expo 2026. The platform features an advanced Liquid Metal Bearing X-ray tube with 360-degree liquid cooling, an Aegis detector system, and configurations supporting up to 128 slices with a 91 cm bore option. This launch expands the company's radiology equipment portfolio beyond MRI machines into high-end diagnostic and surgical CT imaging.
Confidence: HIGH
What changedFischer Medical Ventures officially unveiled its commercial CLARION 64/128-slice CT scanner platform in the Indian market.
Why it mattersBroadens the company's medical imaging product suite from MRI systems into the high-demand CT scanner segment, aligning with its domestic manufacturing and export growth strategy.
CT Slice Configurations: 64/128 slicesBore Size (64-slice): 91 cmCommercial Order Value: not disclosed
📅 Short termShowcases portfolio expansion and technology capability; immediate financial impact depends on converting product showcases into hospital procurement orders.
📈 Long termStrengthens domestic imaging product mix and import-substitution positioning under 'Make-in-India', supporting target revenue diversification.
⚠ Risk flags
- Commercial uptake and order pipeline values not yet disclosed
- Intense competition from established multinational imaging equipment manufacturers
Key Highlights
Launched CLARION CT system available in scalable configurations up to 128 slices
Features 64-slice configuration with a 91 cm bore for vascular and intraoperative imaging
Equipped with Liquid Metal Bearing (LMB) X-ray tube with 360° liquid metal cooling
Incorporates AI-assisted automated patient positioning via a quad-lens depth camera
👀 What to Watch
Track commercial order traction, manufacturing ramp-up at the AP Medtech Zone facility, and revenue contribution from the new CT platform in upcoming quarterly disclosures.
Fischer Medical Unit Wins Catanduanes Digital Healthcare Project in Philippines
Fischer Medical Ventures Limited's step-down subsidiary, Time Medical Philippines (TM-P), has been awarded a province-wide digital healthcare project in Catanduanes Province, Philippines. The rollout involves deploying health kiosks integrated with the PhilHealth-accredited FlynnCare Clinic Management System across municipalities and barangays. While the contract value was not disclosed, this marks the group's first province-wide integrated healthcare implementation supporting the Philippine Universal Health Care initiative. This aligns with the company's international expansion strategy in Southeast Asia across preventive and digital health platforms.
Confidence: MEDIUM
What changedTime Medical Philippines secured a province-wide project award to deploy integrated digital health kiosks and clinic software across Catanduanes Province.
Why it mattersDemonstrates commercial execution of the company's export market strategy in Southeast Asia, validating its preventive care and digital software integration model.
Project Contract Value: not disclosedCompany TTM Revenue: ₹293 CrCompany Market Cap: ₹576 Cr
📅 Short termSentiment positive on international project win, but price impact may be tempered given the absence of quantified contract value.
📈 Long termServes as a reference deployment for scaling similar municipal and provincial digital healthcare projects across the Philippines and broader SEA markets.
⚠ Risk flags
- Contract value and margins not disclosed
- Execution and regulatory risks in overseas jurisdiction
- Concentration on government-led Universal Health Care rollout timelines
Key Highlights
Step-down subsidiary Time Medical Philippines awarded Catanduanes Province digital healthcare project
Integrates Health Kiosks with PhilHealth-accredited FlynnCare Clinic Management System (CMS)
Marks the first province-wide digital health implementation model for the company in the Philippines
Commercial project value and execution timeline were not disclosed in the filing
👀 What to Watch
Track subsequent quarterly financial updates for revenue contributions from Southeast Asian operations and disclosures on contract value or additional provincial rollouts.
Fischer Medical allots 2.05 Cr shares on warrant conversion, raising Rs 35.99 Cr
Fischer Medical Ventures Limited has approved the allotment of 2,05,05,909 equity shares of face value Re 1 each at an issue price of Rs 23.40 per share upon conversion of warrants. The company collected the remaining 75% exercise price of Rs 17.55 per warrant, totaling Rs 35.99 crore in cash. Promoters subscribed to 1,33,35,909 shares (Rs 23.40 crore), while a non-promoter accounted for 71,70,000 shares (Rs 12.58 crore). The inflow represents ~6.2% of the company's Rs 580 crore market capitalization.
Confidence: HIGH
What changedThe company converted 2,05,05,909 share warrants into fully paid equity shares following receipt of the 75% balance consideration.
Why it mattersThe infusion of Rs 35.99 crore provides fresh equity capital to fund business operations and medical tech initiatives, alongside minor equity dilution.
Shares allotted: 2,05,05,909Issue price per share: Rs 23.4075% Consideration received: Rs 35.99 crInflow vs Market cap: ~6.2%Promoter allotment: 1,33,35,909 shares
📅 Short termThe newly issued 2.05 crore shares will be listed and admitted to trading, slightly expanding the equity base while improving liquid cash balances.
📈 Long termContinued promoter participation (~65% of the conversion) demonstrates insider backing for the company's medtech and preventive healthcare strategy.
⚠ Risk flags
- Equity dilution from the addition of 2.05 crore shares
- Execution risk in deploying funds efficiently to sustain top-line growth
Key Highlights
Allotted 2,05,05,909 equity shares of face value Re 1 each at an issue price of Rs 23.40
Received balance 75% consideration of Rs 17.55 per share, totaling Rs 35.99 crore
Promoter entities (Mr. Shankar Varadharajan and FMV Holdings Pte Ltd) contributed Rs 23.40 crore for 1.33 crore shares
Non-promoter Vritti Hitesh Kawa converted 71.70 lakh warrants into equity shares for Rs 12.58 crore
👀 What to Watch
Track the deployment of the Rs 35.99 crore capital into manufacturing automation and working capital, along with the updated shareholding pattern post-allotment.
Fischer Medical Q1 Standalone Loss Widens to ₹3.5 Cr; Allots 2.05 Cr Shares via Warrants
Fischer Medical Ventures reported a weak standalone Q1 (quarter ended June 30, 2026) with revenue declining to ₹0.72 Cr (₹72.17 lakhs) compared to ₹4.54 Cr in the year-ago period. Standalone net loss widened to ₹3.50 Cr (₹350.41 lakhs) from a loss of ₹0.61 Cr in Q1 FY26. The Board also approved the allotment of 2,05,05,909 equity shares at ₹23.40 per share pursuant to warrant conversions, collecting ~₹35.99 Cr in balance conversion consideration. In addition, two Independent Directors (Mr. Roberto M Pagdanganan and Mr. Sanjay Jayantilal Jain) resigned effective August 14, 2026, prompting a reconstitution of key Board committees.
Confidence: HIGH
What changedFischer Medical declared widening standalone Q1 losses, expanded its equity base by 2.05 Cr shares via warrant conversion, and reconstituted board committees following two director exits.
Why it mattersA sharp drop in standalone revenue combined with elevated finance and overhead expenses stresses profitability, while warrant exercise introduces equity dilution.
Standalone Q1 Revenue: ₹72.17 lakhsStandalone Q1 Net Loss: ₹350.41 lakhsShares allotted via warrants: 2,05,05,909Warrant conversion price: ₹23.40 per shareTotal warrant consideration received: ₹35.99 Cr
📅 Short termSentiment is likely to be subdued due to widening standalone losses and simultaneous resignation of two independent directors.
📈 Long termGrowth sustainability depends on operational traction at the AP Medtech Zone facility and scaling consolidated revenues in preventive healthcare and imaging.
⚠ Risk flags
- Widening operating loss at standalone level
- Equity dilution from conversion of 2.05 Cr warrants
- Simultaneous resignation of two Independent Directors
Key Highlights
Standalone Q1 revenue fell sharply to ₹72.17 lakhs from ₹454.23 lakhs in June 2025
Standalone net loss widened to ₹350.41 lakhs against ₹60.94 lakhs in the year-ago quarter
Allotted 2,05,05,909 equity shares of ₹1 each at ₹23.40 per share upon warrant conversion
Received ~₹35.99 Cr across promoters and non-promoters towards warrant balance exercise price (₹17.55/share)
Two Independent Directors resigned simultaneously citing personal reasons, triggering committee reconstitutions
👀 What to Watch
Track consolidated financial performance to gauge full operating health across subsidiaries, and monitor deployment of the ₹35.99 Cr raised from warrant conversions.
Rs 25.06 Cr raised via conversion of 1.43 Cr warrants by Promoters and Investors
Fischer Medical Ventures has allotted 1,42,78,217 equity shares following the conversion of warrants at an exercise price of Rs 23.40 per share. The company received the remaining 75% payment amounting to Rs 25.06 crore from promoters and one non-promoter fund (Vikasa India Eif I Fund). This capital infusion represents approximately 4.3% of the current market capitalization and strengthens the balance sheet for future growth. The conversion price of Rs 23.40 is at a significant discount to the current market price of Rs 38.8.
Confidence: HIGH
What changedThe company converted outstanding warrants into equity shares, resulting in a cash infusion of Rs 25.06 crore and an increase in the total paid-up equity capital.
Why it mattersThis provides the company with necessary liquidity to fund its expansion into mental health and wellness screening while demonstrating continued financial commitment from the promoters.
Total Consideration Received (75%): Rs 25.06 CrIssue Price per Share: Rs 23.40Total Shares Allotted: 1,42,78,217Fundraise vs Market Cap: ~4.3%Fundraise vs TTM Revenue: ~9.6%
📅 Short termThe stock may see neutral to positive sentiment as the capital infusion is finalized, though the equity dilution is now formal.
📈 Long termThe additional capital supports the company's structural shift toward higher-margin preventive healthcare solutions and export market expansion.
⚠ Risk flags
- Equity dilution of approximately 9-10%
- Conversion price is significantly lower than the current market price
Key Highlights
Allotment of 1,42,78,217 equity shares of face value Re 1 each.
Total cash inflow of Rs 25,05,82,708.35 representing the final 75% warrant exercise price.
Promoters Shankar Varadharajan and FMV Holdings Pte Ltd converted a combined 1,12,78,217 warrants.
Non-promoter Vikasa India Eif I Fund converted 30,00,000 warrants.
Issue price fixed at Rs 23.40 per share, including a premium of Rs 22.40.
👀 What to Watch
Investors should monitor the deployment of these funds toward the company's goal of a 50/50 revenue split between Imaging and Preventive Healthcare and its 'Make-in-India' initiatives.
Rs 11.64 Cr raised as Fischer Medical allots 66.31 lakh shares to Promoters via warrant conversion
Fischer Medical Ventures has allotted 66,31,664 equity shares to its promoters following the conversion of warrants. The company received the remaining 75% of the exercise price, totaling Rs 11.64 crore in cash. The shares were issued at Rs 23.40 each, which represents a significant discount to the current market price of Rs 37.7. This capital infusion by the promoters demonstrates continued commitment to the company's growth strategy in the medical equipment sector.
Confidence: HIGH
What changedThe company converted 66.31 lakh warrants into equity shares, resulting in a cash inflow of Rs 11.64 crore and an increase in the total paid-up equity capital.
Why it mattersThis provides the company with additional liquidity to fund its expansion into preventive healthcare and mental health screening, while signaling promoter confidence in the business's long-term value.
Shares Allotted: 66,31,664Issue Price per Share: Rs 23.40Total Consideration Received: Rs 11.64 CrFundraise vs Market Cap: ~2.06%Current Market Price: Rs 37.7
📅 Short termThe news is likely to be viewed positively by the market as it confirms promoter backing and provides immediate cash flow, though the equity dilution is a factor to consider.
📈 Long termThe capital supports the company's goal of a 50/50 revenue split between Imaging and Preventive Healthcare, which is expected to drive higher margins over the next 3 years.
⚠ Risk flags
- Equity dilution for minority shareholders
- Issue price is at a ~38% discount to current market price
Key Highlights
Allotment of 66,31,664 equity shares of face value Re 1 each to the promoter group.
Total cash consideration of Rs 11,63,85,703 received as the final 75% payment for warrant conversion.
Issue price fixed at Rs 23.40 per share, including a premium of Rs 22.40.
Promoter FMV Holdings Pte Ltd received the bulk of the allotment with 54,31,664 shares.
Capital infusion represents approximately 2.06% of the current market capitalization of Rs 565 Cr.
👀 What to Watch
Investors should monitor the upcoming shareholding pattern to see the exact increase in promoter stake and watch for management commentary on the utilization of these funds for their 'Make-in-India' initiatives.
First Installation: Fischer Medical Subsidiary Partners for AI-Enabled iMRI Suite in Vadodara
Fischer Medical Ventures Limited, through its subsidiary Time Medical India, has announced its first partnership to install the DRIS–iMRI Medharanya Suite at Parul Sevashram Hospital, Vadodara. This AI-enabled portable intraoperative MRI system provides real-time visualization during complex neurosurgeries, integrating AR, ML, and Exoscope technologies. While the specific contract value was not disclosed, the partnership leverages Parul University's ecosystem of 43,000+ students for clinical validation. This move aligns with the company's strategy to scale its imaging segment, which contributed to a 120% revenue growth in H1 FY26.
Confidence: HIGH
What changedFischer Medical has moved from the development phase to the first clinical deployment of its specialized intraoperative MRI technology in India.
Why it mattersThis installation serves as a critical reference site for the company's high-margin imaging segment. Successful deployment at a major teaching hospital validates the technology and supports the company's goal to achieve a 50/50 revenue split between Imaging and Preventive Healthcare.
TTM Revenue: ₹260 CrPartner University Student Base: 43,000+Order Value: not disclosedTTM PAT: ₹39 Cr
📅 Short termThe announcement is likely to be viewed positively as it demonstrates technological progress and institutional acceptance of their 'Make-in-India' MRI solutions.
📈 Long termIf the company successfully scales these specialized MRI suites across its target MENA and SEA markets, it could significantly improve operating margins and structural positioning in the high-end medical equipment space.
⚠ Risk flags
- Lack of disclosed financial value for the partnership
- Execution risk associated with the first-time installation of complex medical hardware
- High competition from established global radiology equipment manufacturers
Key Highlights
First clinical installation of the proprietary DRIS–iMRI Medharanya Suite at Parul Sevashram Hospital.
Partner institution Parul University hosts a student community of over 43,000 across 34 institutes.
Technology integrates AI, Machine Learning, and Augmented Reality for real-time neurosurgical guidance.
Fischer Medical reported TTM revenue of ₹260 Cr and a PAT of ₹39 Cr as of the latest filings.
The system was developed in collaboration with globally renowned neurosurgeon Dr. Iype Cherian.
👀 What to Watch
Investors should monitor the successful commissioning of this suite and look for subsequent orders from other medical institutions to gauge the commercial scalability of this high-tech product. The ability to convert this 'first-of-its-kind' installation into a recurring order book will be key to achieving the company's 15-20% growth target.
Fischer Medical Secures CDSCO Approval for Spincare; Targets $380M Indian Wound Care Market
Fischer Medical Ventures' associate company, Nanomedic Technologies (Israel), has received CDSCO Class C import approval for the Spincare Portable Wound Care System. Fischer holds exclusive distribution rights for this first-of-its-kind electrospun technology across India and Southeast Asia. The Indian wound care market is valued at $380 million in 2026 and is projected to reach $1.8 billion by 2033. This regulatory milestone allows the company to begin commercial deployment in hospitals and burn centers, diversifying its revenue stream beyond medical imaging.
Confidence: HIGH
What changedFischer Medical has transitioned from a regulatory waiting phase to having full legal clearance to import and distribute a unique, portable wound care system in India.
Why it mattersThis represents a major step in the company's strategy to achieve a 50/50 revenue split between Imaging and Preventive Healthcare. It grants Fischer entry into a high-growth, high-margin medical device niche with exclusive regional rights.
India Wound Care Market (2026): USD 380 millionProjected India Market (2033): USD 1.8 billionSEA Market Projection (2030): USD 354 millionTTM Revenue: Rs 260 CrProduct Shelf Life: 5 years
📅 Short termThe stock may see positive sentiment as this approval validates the company's expansion into advanced medical technologies and opens a new revenue channel.
📈 Long termIf successfully executed, this product could significantly contribute to the company's 15-20% growth target and re-rate the business as a diversified med-tech provider rather than just an imaging company.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in establishing a new sales network for wound care
- Dependency on Israeli associate for product supply
- Competition from traditional wound dressing manufacturers
Key Highlights
Received CDSCO Import Permission No. IMP/MD/2026/000455 for a Class C Medical Device
Secured exclusive distribution rights for India and Southeast Asia markets
Targeting an Indian wound care market projected to grow at a 6.4% CAGR to $1.8 billion by 2033
Southeast Asia advanced wound care segment projected to reach $354 million by 2030
Product features a five-year shelf life and uses proprietary electrospinning technology
👀 What to Watch
Monitor the timeline for the first commercial orders and hospital tie-ups in India. Watch for the outcome of the pending US FDA approval application by the associate company, which would serve as a global quality benchmark.
Fischer Medical Ventures FY26 Net Profit Surges to ₹31.02 Cr; Recommends ₹0.05 Dividend
Fischer Medical Ventures reported a massive turnaround for the full year ended March 31, 2026, with consolidated revenue jumping to ₹308.58 crore from ₹110.70 crore in the previous year. Annual consolidated net profit skyrocketed to ₹31.02 crore compared to just ₹1.21 crore in FY25. Despite the strong annual performance, the company recorded a consolidated net loss of ₹7.12 crore in Q4 FY26. The Board has recommended a final dividend of ₹0.05 per equity share.
Key Highlights
Consolidated annual revenue from operations grew by 178.7% YoY to ₹30,857.56 Lakhs.
Full-year consolidated net profit increased significantly to ₹3,101.94 Lakhs from ₹120.79 Lakhs in FY25.
Board recommended a final dividend of ₹0.05 per equity share for FY 2025-26.
Consolidated Basic EPS improved to ₹0.48 for FY26 from ₹0.02 in the previous year.
The company reported a consolidated net loss of ₹711.94 Lakhs in Q4 FY26 against a profit of ₹131.22 Lakhs in Q4 FY25.
👀 What to Watch
Investors should view the massive annual growth and turnaround as a strong positive, though the Q4 loss warrants a closer look at operating margins and expense spikes. The initiation of a dividend is a positive signal of management's confidence in cash flows.
Fischer Medical FY26 Consolidated Net Profit Surges to ₹31.02 Cr; ₹0.05 Dividend Declared
Fischer Medical Ventures reported a massive 186% year-on-year increase in consolidated total income for FY26, reaching ₹32,088.93 Lakhs. The annual consolidated net profit saw a significant jump to ₹3,101.94 Lakhs compared to just ₹120.79 Lakhs in FY25. Despite the strong annual performance, the company recorded a consolidated net loss of ₹709.78 Lakhs in Q4 FY26, primarily driven by a sharp increase in other expenses. The board has also recommended a final dividend of ₹0.05 per equity share.
Key Highlights
Consolidated FY26 Total Income rose to ₹32,088.93 Lakhs from ₹11,219.07 Lakhs in FY25.
Full-year Consolidated Net Profit increased significantly to ₹3,101.94 Lakhs from ₹120.79 Lakhs YoY.
Board recommended a final dividend of ₹0.05 per equity share (Face Value ₹1).
Q4 FY26 consolidated results showed a net loss of ₹709.78 Lakhs versus a profit of ₹131.22 Lakhs in Q4 FY25.
Standalone FY26 performance reported a net loss of ₹1,042.29 Lakhs, indicating most value resides in subsidiaries.
👀 What to Watch
The massive consolidated growth suggests the company's transition into medical ventures is scaling rapidly, though investors should investigate the cause of the Q4 loss and high 'Other Expenses'. Monitor the sustainability of subsidiary profits as the standalone entity remains loss-making.
Fischer Medical Subsidiary Signs Landmark Global Neurosurgical Tech Partnership with WFNS
Fischer Medical Ventures' subsidiary, Time Medical India, has secured a historic partnership with the WFNS Innovation & Technology Committee. This is the first time the WFNS committee has formally partnered with a private industry participant to advance global neurosurgical innovation. The collaboration will focus on high-end medical imaging, including intraoperative MRI suites and specialized brain aneurysm screening technologies. This strategic alliance enhances the company's global standing and provides a platform for disseminating its advanced diagnostic solutions worldwide.
Key Highlights
First-ever industry partnership formally established by the WFNS Innovation & Technology Committee.
Focus on advanced technologies including single-room intraoperative MRI and Exoscope visualization.
Collaboration covers global training, knowledge-sharing, and technology transfer initiatives for neurosurgical care.
Targets improved precision and patient outcomes in neuro-imaging across both emerging and developed markets.
👀 What to Watch
This partnership provides significant global validation for Fischer’s medical technology; investors should monitor how this association translates into international order book growth and market penetration.
Fischer Medical Allots 60 Lakh Shares to Promoter; Raises Rs 10.53 Cr via Warrant Conversion
Fischer Medical Ventures Limited has approved the allotment of 60,00,000 equity shares to its promoter, Mr. Shankar Varadharajan, following the conversion of warrants. The shares were issued at a price of Rs. 23.40 per share, which includes a premium of Rs. 22.40. The company received a total cash consideration of Rs. 10.53 crores, representing the final 75% payment required for the conversion. This move increases the promoter's equity stake and provides the company with fresh growth capital.
Key Highlights
Allotment of 60,00,000 equity shares of face value Re. 1 each
Issue price of Rs. 23.40 per share, including a premium of Rs. 22.40
Total consideration of Rs. 10,53,00,000 received for the remaining 75% exercise price
Allottee is Mr. Shankar Varadharajan, belonging to the Promoter category
Conversion completed via Circular Resolution dated March 31, 2026
👀 What to Watch
Investors should view the promoter's decision to exercise warrants as a strong signal of confidence in the company's valuation and future growth. The capital infusion of over Rs. 10 crore should be monitored for its impact on upcoming medical technology projects.
Fischer Medical Ventures Subsidiary Acquires 75% Stake in Indonesian Medical Firm
Fischer Medical Ventures Limited's wholly owned subsidiary, FMV Global Innovations Pte Limited, has acquired a 75% stake in PT Fischer Pariko Medical Ventures. The target entity is a newly incorporated Indonesian company focused on the wholesale of medical, scientific, and precision equipment. As the entity was incorporated in October 2024, it reported nil turnover for the 2024-25 period. This acquisition marks a strategic expansion for Fischer Medical into the Southeast Asian healthcare market.
Key Highlights
Acquisition of 75% stake in PT Fischer Pariko Medical Ventures via a 100% owned subsidiary.
Target entity is based in Indonesia and operates in the healthcare and medical equipment wholesale industry.
The acquired company is a startup incorporated on October 14, 2024, with nil revenue for FY24-25.
The move signifies an international expansion strategy into the Indonesian medical equipment market.
👀 What to Watch
Investors should monitor the operational progress of this new Indonesian venture as it begins generating revenue. While the acquisition is strategic, the target is a startup, so immediate financial impact will be limited.
Fischer Medical Launches India's First Helium-Free 1.5T MRI Platforms MICA and QUIN
Fischer Medical Ventures Limited, through its subsidiary Time Medical India, has launched two advanced 1.5T MRI platforms, MICA and QUIN, at IRIA 2026. QUIN is distinguished as India's first helium-free 1.5T wide 70 cm bore MRI system, which eliminates helium dependency and simplifies installation. Both systems have secured CDSCO certification, allowing for immediate commercial rollout in the Indian healthcare market. These launches represent a significant technological milestone for the company in the sustainable medical imaging sector.
Key Highlights
Launched QUIN, India's first helium-free 1.5T wide 70 cm bore MRI system.
Introduced MICA, a 1.5T 32-channel MRI with 1000-litre zero boil-off magnet technology.
Both MRI platforms have received mandatory CDSCO certification for the Indian market.
QUIN features a no-quench-pipe auto ramp unit, reducing infrastructure requirements.
Systems are available in 32 and 64-channel configurations for high-resolution imaging.
👀 What to Watch
The launch of India's first helium-free MRI technology positions Fischer as a leader in cost-effective medical imaging. Investors should watch for order book growth and hospital partnerships following this launch.
Fischer Medical Subsidiary Secures Rs 40 Crore Loan from HDFC Bank
Fischer Medical Ventures' material subsidiary, Time Medical International Ventures (India) Private Limited, has entered into a secured loan agreement with HDFC Bank for Rs 40 Crores. The loan carries an interest rate of 3 months Repo plus 2.75% per annum. The facility is secured by a pledge of shares and Fixed Deposit collateral. This capital infusion will likely support the subsidiary's operational requirements or growth initiatives.
Key Highlights
Loan amount of Rs 40 Crores sanctioned by HDFC Bank to the material subsidiary.
Interest rate set at 3 months Repo rate + 2.75% per annum.
Loan is secured through pledged shares and Fixed Deposit (FD) collateral.
Agreement approved by the Board of Directors on January 30, 2025.
👀 What to Watch
Investors should monitor the utilization of these funds and the subsequent impact on the subsidiary's revenue growth. The debt addition is manageable given the secured nature and competitive interest pricing.
Fischer Medical Q3 FY26 Consolidated Revenue Surges to ₹101 Cr; PAT at ₹19.2 Cr
Fischer Medical Ventures reported a massive jump in consolidated revenue to ₹10,109.52 Lakhs for Q3 FY26, compared to ₹1,174.85 Lakhs in the same quarter last year. The company turned profitable on a consolidated basis with a PAT of ₹1,923.48 Lakhs, a significant recovery from a loss of ₹29.39 Lakhs in Q3 FY25. For the nine-month period, consolidated revenue reached ₹21,084.52 Lakhs, marking a substantial growth over the previous year's ₹6,152.45 Lakhs. However, the standalone business reported a loss of ₹166.93 Lakhs for the quarter, indicating that growth is heavily driven by its subsidiaries.
Key Highlights
Consolidated revenue grew by approximately 760% YoY to ₹10,109.52 Lakhs in Q3 FY26.
Consolidated PAT turned positive at ₹1,923.48 Lakhs versus a loss of ₹29.39 Lakhs in the previous year's quarter.
Nine-month consolidated PAT stands at ₹3,813.89 Lakhs compared to a loss of ₹10.42 Lakhs in the prior period.
Board approved restructuring of Malaysian subsidiary Fischer Hospitality Sdn. Bhd. with a trustee holding 51%.
Company Secretary and Compliance Officer Mr. Aravindkumar V resigned effective February 10, 2026.
👀 What to Watch
The massive consolidated growth and turnaround to profitability are strong positive signals, though investors should note that the standalone entity remains in a loss. Monitor the appointment of the new Compliance Officer and the progress of the Malaysian subsidiary restructuring.
Fischer Medical Ventures enters Indonesia for TB Eradication
Fischer Medical Ventures Limited, through its subsidiary Time Medical International Ventures (India) Pvt Ltd, is entering Indonesia via a TB eradication partnership with the City of Jember. This collaboration involves PT Pariko and includes a pilot deployment of 250 AI-powered X-ray systems by March 2026. The order size is approximately USD 6.5 million, positioning FMV as a strategic partner in Indonesia’s public healthcare initiatives. This expansion could positively impact the company's revenue stream in the coming years.
Key Highlights
Time Medical International Ventures (India) Pvt Ltd enters Indonesia
Pilot deployment of 250 units of AI-powered X-ray systems planned by March 2026
Order size is approximately USD 6.5 million
Partnership with the City of Jember for TB eradication
👀 What to Watch
Investors should monitor the progress of the pilot deployment and the potential for further expansion in Indonesia. Keep an eye on revenue growth related to this international venture.
